Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Merck’s guidance was affected because it decided to pause shipments of Gardasil to China from February through at least the ...

Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, though the drug company’s outlook for 2025 ...

Kennedy for years has earned referral fees from Wisner Baum, a Los Angeles personal injury law firm that is currently suing Merck ... to a limited liability company managed by Del Gibtree ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

With CHMP endorsement in hand, Merck looks to win final marketing authorization from the European Commission in the second quarter of this year, according to a company press release. Already in ...

RAHWAY, N.J. - Merck & Co ., Inc. (NYSE:MRK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its pneumococcal ...

Shares of this pharmaceutical company have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.2% change. The Zacks Large Cap Pharmaceuticals industry, to which Merck ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $118.00. The company’s shares opened today at ...